ArticlePharmaceuticals (Basel, Switzerland)2013
Advances in Mammalian cell line development technologies for recombinant protein production.
Article in Pharmaceuticals (Basel, Switzerland), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed.
- Combining gene amplification with SEAP-reporter to achieve high expression of recombinant omicron XBB.1.5 spike protein.Protein expression and purification · 2027Article
- Trimeric hemagglutinin vaccine provides chickens complete protection against lethal H5 subtype avian influenza virus from clade 2.3.4.4b.Emerging microbes & infections · 2026Article
- Article
- Streamlined stable CHO cell line development using droplet microfluidics with image-based monoclonality assessment.Bioprocess and biosystems engineering · 2026Article
- Development of predictable and high-yield CHO cell line by site-specific integration.Journal of biological engineering · 2025Article
- Structural and Functional Characterization of Anti-SARS-CoV-2 Spike Monoclonal Antibodies Produced via Bicistronic Expression in CHO Cells.Antibodies (Basel, Switzerland) · 2025Article
- Development of a point-of-care test for the simultaneous detection of respiratory syncytial virus and IL-33 as a disease biomarker in children.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Immunogenicity and cellular response of a herpes zoster virus gEgI fusion protein adjuvanted with CpG-emulsion in mice.Journal of nanobiotechnology · 2025Article
- BeyondChemical reviews · 2025Review
- Accelerating biopharmaceutical cell line selection with label-free multimodal nonlinear optical microscopy and machine learning.Communications biology · 2025Article
- Sequence and Configuration of a Novel Bispecific Antibody Format Impacts Its Production Using Chinese Hamster Ovary (CHO) Cells.Biotechnology and bioengineering · 2025Article
- Single-cell cloning and its approaches.Frontiers in cell and developmental biology · 2025Review
- A Multi Clone Kinetic Model for characterizing Chinese hamster ovary cell line variability.Journal of industrial microbiology & biotechnology · 2024Article
- SWATH-MS insights on sodium butyrate effect on mAbs production and redox homeostasis in CHO cells.AMB Express · 2024Article
- Context-dependent genomic locus effects on antibody production in recombinant Chinese hamster ovary cells generated through random integration.Computational and structural biotechnology journal · 2024Article
- Review
- Extracellular vesicle depletion and UGCG overexpression mitigate the cell density effect in HEK293 cell culture transfection.Molecular therapy. Methods & clinical development · 2024Article
- Construction of a novel kinetic model for the production process of a CVA6 VLP vaccine in CHO cells.Cytotechnology · 2024Article
- Enhancing protein production and growth in chinese hamster ovary cells through miR-107 overexpression.AMB Express · 2024Article
- Generation of Monoclonal Chinese Hamster Ovary Cell Lines Using DISPENCELL-S3.Methods in molecular biology (Clifton, N.J.) · 2024Article
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
From 2006 to 2011, an average of 15 novel recombinant protein therapeutics have been approved by US Food and Drug Administration (FDA) annually. In addition, the expiration of blockbuster biologics has also spurred the emergence of biosimilars. The increasing numbers of innovator biologic products and biosimilars have thus fuelled the demand of production cell lines with high productivity. Currently, mammalian cell line development technologies used by most biopharmaceutical companies are based on either the methotrexate (MTX) amplification technology or the glutamine synthetase (GS) system. With both systems, the cell clones obtained are highly heterogeneous, as a result of random genome integration by the gene of interest and the gene amplification process. Consequently, large numbers of cell clones have to be screened to identify rare stable high producer cell clones. As such, the cell line development process typically requires 6 to 12 months and is a time, capital and labour intensive process. This article reviews established advances in protein expression and clone screening which are the core technologies in mammalian cell line development. Advancements in these component technologies are vital to improve the speed and efficiency of generating robust and highly productive cell line for large scale production of protein therapeutics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.